Ultragenyx Pharmaceutical | RARE - Operating Profit

Stock Price
31.75
Daily Change
-0.07 -0.22%
Monthly
13.19%
Yearly
-42.52%
Q3 Forecast
31.56

Ultragenyx Pharmaceutical reported $-193567000 in Operating Profit for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.31B
Cash and Equivalent USD 166.11M
Cost of Sales USD 23M
Current Assets USD 719.79M
Current Liabilities USD 293.24M
Debt USD 36.3M
EBIT USD -193.57M
EBITDA USD -91.34M
Employees 1.29K
EPS Earnings Per Share USD -1.17
Equity Capital and Reserves USD 151.29M
Gross Profit on Sales USD 143.49M
Interest Expense on Debt 14.04M
Interest Income USD 5.79M
Loan Capital USD 782.75M
Market Capitalization USD 2.61B
Net Income USD -114.95M
Operating Expenses USD 274.38M
Operating Profit USD -193.57M
Ordinary Share Capital USD 96.35M
Pre-Tax Profit USD -114M
Sales Revenues USD 166.5M
Selling and Administration Expenses USD 86.65M
Stock USD 46.5M
Trade Creditors USD 34.24M
Trade Debtors USD 124.46M

Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Insmed USD -253876000 5.74M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Kyowa Hakko Kirin JPY 12.82B 5.39B Jun/2025
MacroGenics USD -36760000 20.17M Jun/2025
Moderna USD -907000000 143M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025